CTOs on the Move

DeGolers Pharmacies

www.degoler.com

 
DeGolers Pharmacies is a Kansas City, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.degoler.com
  • 7622 State Ave
    Kansas City, KS USA 66112
  • Phone: 913.596.2447

Executives

Name Title Contact Details

Similar Companies

International Labs

International Labs is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BrainStorm Cell

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.

Cardiocore Lab, Inc.

Cardiocore Lab, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.

Integrum

Integrum has since its foundation been helping amputees towards an improved quality of life. We specialize in the osseointegration method.